Browsing by Author "Lee, Ming Ta Michael"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update
    (Wiley, 2021) Karnes, Jason H.; Rettie, Allan E.; Somogyi, Andrew A.; Huddart, Rachel; Fohner, Alison E.; Formea, Christine M.; Lee, Ming Ta Michael; Llerena, Adrian; Whirl-Carrillo, Michelle; Klein, Teri E.; Phillips, Elizabeth J.; Mintzer, Scott; Gaedigk, Andrea; Caudle, Kelly E.; Callaghan, John T.; Medicine, School of Medicine
    Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).
  • Thumbnail Image
    Item
    Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing
    (Nature Publishing Group, 2014-11) Caudle, Kelly E.; Rettie, Allan E.; Whirl-Carrillo, Michelle; Smith, Lisa H.; Mintzer, Scott E.; Lee, Ming Ta Michael; Klein, Teri E.; Callaghan, J. Thomas; Department of Neurology, IU School of Medicine
    Phenytoin is a widely used antiepileptic drug with a narrow therapeutic index and large inter-patient variability partly due to genetic variations in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotype (also available on PharmGKB: www.pharmgkb.org).
  • Thumbnail Image
    Item
    Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen B (HLA-B) Genotype and Allopurinol Dosing: 2015 update
    (Wiley, 2016-01) Saito, Yoshiro; Stamp, Lisa K.; Caudle, Kelly E.; Hershfield, Michael; McDonagh, Ellen M.; Callaghan, John T.; Tassaneeyakul, Wichittra; Mushiroda, Taisei; Kamatani, Naoyuki; Goldspiel, Barry R.; Phillips, Elizabeth J.; Klein, Teri E.; Lee, Ming Ta Michael; Department of Pharmacology and Toxicology, IU School of Medicine
    The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).
  • Thumbnail Image
    Item
    PharmVar GeneFocus: CYP2C19
    (Wiley, 2021) Botton, Mariana R.; Whirl-Carrillo, Michelle; Del Tredici, Andria L.; Sangkuhl, Katrin; Cavallari, Larisa H.; Agúndez, José A.; Duconge, Jorge; Lee, Ming Ta Michael; Woodahl, Erica L.; Claudio-Campos, Karla; Daly, Ann K.; Klein, Teri E.; Pratt, Victoria M.; Scott, Stuart A.; Gaedigk, Andrea; Medicine, School of Medicine
    The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation impacts the metabolism of many drugs and has been associated with both efficacy and safety issues for several commonly prescribed medications. This GeneFocus provides a comprehensive overview and summary of CYP2C19 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase and the Clinical Pharmacogenetics Implementation Consortium (CPIC).